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Abstract 
Chronic elevation of pulmonary microvascular pressure (Pmv) consistently leads to alveolocapillary 
barrier thickening and reduction in the filtration coefficient.  In animal models of chronic heart failure (CHF) 
the lung remains dry despite hydrostatic forces.  As fluid flux is bi-directional, it has been postulated that an 
increase in alveolar fluid clearance may facilitate the dry lung when Pmv is chronically elevated. In this study 
we aimed to examine alveolar fluid clearance in ambulatory patients with CHF secondary to left ventricular 
(LV) systolic dysfunction compared against non-CHF controls. Lung clearance following aerosol delivery of 
99m
technetium (Tc)-diethyl triaminepentaacetic acid (DTPA) was measured non-invasively by scintigraphy and 
half time of 
99m
Tc-DTPA clearance (T (1/2)) was calculated by mono-exponential curve fit.  Alveolar fluid 
clearance measured as half time DTPA clearance was significantly faster in CHF patients than controls (P = 
0.001).  This was further defined by NYHA classification.  No correlation was found between DTPA clearance 
and plasma epinephrine, norepinephrine or aldosterone hormone (P > 0.05).  Our results support an association 
between increasing alveolar fluid clearance and disease severity in CHF, and the concept of controlled bi-
directional fluid flux in CHF associated with increasing Pmv, and represents another defence mechanism of the 
lung against pulmonary oedema.   
 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
4 
Introduction 
Chronic elevation of pulmonary microvascular pressure (Pmv) consistently leads to thickening of the 
endothelial and epithelial basement membranes, and reduction in the filtration coefficient [1, 2].  In animal 
models of chronic heart failure (CHF) there is strain dependent variation in the balance between fibrotic 
remodelling and alveolar type II cell (ATII) hyperplasia, likely reflecting clinical differences in response to 
chronic elevation of Pmv. However, all models manifest a heavier dry lung without apparent pulmonary 
oedema despite hydrostatic forces favouring its development [2-5].  As fluid flux is bi-directional it has been 
postulated that an increase in alveolar fluid clearance (outflow) may facilitate the dry lung when Pmv is 
chronically elevated and favouring fluid influx [6, 7]. 
Using a rodent model of CHF, we recently demonstrated increased tolerance of the ex vivo isolated 
perfused lung to acute left atrial pressure elevation, but reduced clearance of alveolar lung fluid in the non-
perfused isolated lung [8].  These processes occurred on a background of increased dry lung weight, previously 
found to correlate with lung collagen and a decrease in endothelial aquaporin (AQP)1 [5, 8].  These data are 
consistent with reduced bi-directional fluid flux due to both structural and cellular remodelling.  Preliminary 
clinical data from patients admitted to ICU with acute pulmonary oedema similarly suggested slower plasma 
refill in patients with CHF compared to patients without, which we hypothesised may be due to slower alveolar 
clearance of oedema fluid [8]. In a previous study, again utilising the rodent model of CHF, we found greater 
lung accumulation of the intravascular hydrophilic radio marker
 99m
technetium (Tc)-diethyl triaminepentaacetic 
acid (DTPA), suggesting increased pulmonary permeability in vivo in animals with CHF [4].  
In this study we aimed to further clarify these findings clinically by examining alveolar fluid clearance 
in ambulatory patients with CHF secondary to left ventricular (LV) systolic dysfunction compared against non-
CHF controls. The study complies with the Declaration of Helsinki, the protocol was approved by the Flinders 
Clinical Research Ethics Committee, Flinders Medical Centre, and all participants provided written informed 
consent. 
 
Methods 
Adult participants attending Flinders Medical Centre, Adelaide, Australia were classified as: CHF - a 
clinical diagnosis of CHF of at least 6 months duration, or non-CHF - no history of heart failure in healthy 
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volunteers recruited through poster advertisement, age and gender matched to CHF patients.  Lung clearance 
following aerosol delivery of 
99m
Tc-DTPA was measured non-invasively by scintigraphy with a γ-camera in the 
Dept. of Medical Imaging, using standard nuclear medicine diagnostic protocols, as previously described [9]. 
Half time of 
99m
Tc-DTPA clearance (T (1/2)) was calculated by mono-exponential curve fit.  Plasma 
epinephrine, norepinephrine (Abnova Corp, Taiwan) and aldosterone (Cayman Chemical, Ann Arbor, MI) were 
assessed by Enzyme Linked Immunosorbent Assay. 
Continuous data are presented as median (25
th
-75
th
 percentiles) and analysed by Jonkheere-Terpstra test 
for ordered variables, 2 groups by Mann-Whitney U test and categorical variables as number (%) and analysed 
by Chi-square test. Correlations were examined by Pearsons Correlation.  P ≤ 0.05 was considered significant. 
 
Results 
Participants differed only in cardiac parameters (Table 1). Alveolar fluid clearance measured as half 
time DTPA clearance was significantly faster in CHF patients than controls (55.1 (47.6-71.6) versus 75.9 (70.3-
84.8) min, median (25th-75th percentiles); P=0.001).  This was further defined by NYHA classification (Table 
2).  No difference was found in any measured plasma hormone between groups, nor was any correlation found 
between DTPA clearance and plasma hormone (P > 0.05).  There was however a significant correlation 
between norepinephrine and aldosterone (r
2
 = 0.416, P = 0.007, by Pearson correlation). 
 
Discussion 
This study aimed to reconcile the conflicting findings from previous investigations into alveolar fluid 
regulation in CHF via the utilisation of a sensitive and specific marker of fluid movement in a well-defined 
patient cohort compared against matched non-CHF controls.   
Lung water in CHF is increasingly recognised as a complex but critical component of the CHF 
syndrome which is incompletely understood pathophysiologically [10] and has been historically under 
recognised. Indeed, in recent clinical studies of discharge decompensated CHF, the presence of congestion on 
chest X-ray or via increased ultrasound B-lines is independently predictive of poor clinical outcome 
(hospitalisation and mortality) [10, 11].  
Our results appear to support an association between increasing alveolar fluid clearance and disease 
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severity in CHF. This result supports previous animal investigations in isolated perfused lungs from volume 
overload CHF [12, 13], as well as the trend observed in a decompensated patient population [14], in which 
there is an increase in alveolar fluid clearance, but is inconsistent with our previous findings in the isolated non-
perfused rat lung [8].  
In looking at this result it is important therefore to examine the difference between models used. In non-
perfused isolated CHF rat lungs ex vivo we showed reduced alveolar fluid clearance [8]. In the study by Kaestle 
et al [13] alveolar fluid clearance was examined in perfused isolated CHF lungs ex vivo and increased rate of 
clearance reported. However, this increase was only apparent when left atrial pressure was raised to 15cmH2O. 
This suggests that there is a change in the rate of alveolar fluid clearance dependant on current Pmv. In chronic 
renal failure dialysis patients an increased rate of DTPA clearance from lungs is found to decrease after 
dialysis, ie following reduction in intravascular volume and therefore Pmv [15]. This suggests that while Pmv is 
high, such as in severe CHF (NYHA III) or the intravascular overloaded state of pre-dialysis, alveolar clearance 
increases with increased fluid influx, but when Pmv is lower (NYHA II) or at the end of dialysis following loss 
of intravenous volume, the rate of fluid flux is decreased, thereby manifesting as slower clearance.   
Whether the clinically important presence of ongoing excess lung water in decompensated CHF 
represents a failure adequate lung fluid clearance or an issue of timing in the dynamic decompensated state is 
unknown [10, 11]. The model of increased Pmv resulting in increased fluid influx balanced by increased fluid 
clearance does not hold in models of acute heart failure, or acute rise in Pmv, where alveolar fluid clearance has 
been found to decrease and pulmonary oedema manifest [13, 16-18].  Therefore, we may assume that in the 
presence of chronically elevated Pmv the pulmonary system is intrinsically changed in a manner which 
facilitates an increase in alveolar fluid clearance in parallel with increased fluid input, but that this can be 
overwhelmed, possibly by a sudden Pmv increase, or which may be less effective in a cohort of patients.  In 
order to adequately understand the relationship between bi-directional fluid flux and Pmv we must therefore 
examine the controlling mechanisms. 
It has been suggested that increased rate of alveolar fluid clearance in CHF may be due to an increase in 
the absolute expression and activation of vectorial fluid channels on both endothelial and epithelial cells, 
controlled through a nitric oxide negative feedback mechanism [12, 13]. This mechanism, which allows for an 
increase in fluid flux capacity of the lung in CHF, provides a possible explanation for our previous finding of 
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resistance to elevation in Pmv in isolated perfused lungs from CHF. However, in order to explain our finding of 
decreased alveolar clearance in the non-perfused CHF lung, this mechanism would necessitate a sequential 
activation whereby the endothelium is activated prior to activation of these channels on the epithelium.  In 
addition, changes in the expression of these channels have not been consistently observed, including in our 
animal study [8, 12].   
Tandon and Kasturi first reported that in patients with CHF from mitral stenosis, pulmonary 
remodelling in response to chronically elevated Pmv results not only in thickening of the alveolocapillary 
barrier, but also in dilatation of the lymphatics [19]. This was supported more recently using ultrasound where 
patients with CHF were found to have an average thoracic duct diameter of 6.3mm in comparison with 2.5 mm 
in healthy subjects [20]. While this increase in lymphatic diameter provides for greater capacity for removal of 
accumulated interstitial fluid due to elevated Pmv in the isolated perfused lung or whole animal, in the absence 
of arterial pressure or mechanical muscle forces in our non-perfused, non-ventilated lung, this enhanced lymph 
drainage system would be less effective [21, 22]. In conclusion, this study supports the concept of controlled bi-
directional fluid flux in CHF associated with increasing Pmv and represents another defence mechanism of the 
lung against pulmonary oedema.  This increase in clearance rate may be due to enhanced lymphatic drainage 
with a contribution by specific ion and water channels, however, the mechanisms facilitating the dry lung in 
CHF require further elucidation.    
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Table 1. Baseline Characteristics  
 Control CHF - NYHA II CHF - NYHA III P ≤ 
n 8 5 5  
Age (years) 65 (53-71) 56 (53-63) 63 (62-71) 0.68 
Gender (male) 5 (63) 4 (80) 3 (60) 0.76 
Hypertension 3 (38) 2 (40) 2 (40) 0.99 
Diabetes 1 (13) 0 (0) 2 (40) 0.22 
Inflammatory Disease 1 (13) 0 (0) 0 (0) 0.09 
Atrial Fibrillation 0 (0)a 3 (60)b 2 (40)ab 0.05 
Smoking <5yr cessation 0 (0) 0 (0) 0 (0) 1.00 
Alcohol >2 glasses/day 1 (13) 0 (0) 0 (0) 0.09 
Medications (Yes)     
Spironolactone 0 (0)a 5 (100)b 5 (100)b 0.001 
ACE Inhibitors 0 (0)a 5 (100)b 3 (60)b 0.001 
ARB 1 (11) 0 (0) 2 (40) 0.42 
-Blocker 1 (11)a 5 (100)b 5 (100)
b 0.001 
Loop Diuretic 0 (0)a 4 (80)b 4 (80)b 0.001 
Statins 0 (0)a 0 (0)a 4 (80)b 0.003 
Aspirin 1 (11) 0 (0) 3 (60) 0.12 
Digoxin 0 (0) 1 (20) 0 (0) 0.56 
Amiodarone 0 (0) 0 (0) 1 (20) 0.56 
Echocardiogram     
LVEDD (cm) - 6.1 (5.5-6.5) 6.2 (5.1-6.9) 0.84 
Ejection Fraction (%) - 29 (23-34) 35 (24-36) 0.55 
LA size (cm2) - 24 (20-38) 30 (18-38) 1.00 
IVC size (cm) - 2.1 (2.0-) 2.5 (2.0-) 0.40 
E:E’ - 12 (10-15) 15 (9-21) 0.69 
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Continuous data are presented as median (25th-75th percentiles) and analysed by 
Jonkheere-Terpstra test for ordered variables, 2 groups by Mann-Whitney U test and 
categorical variables as number (%) and analysed by Chi-square test. Superscripts 
represent differences by pairwise comparison at P ≤ 0.05.  ACE, angiotensin-converting 
enzyme; ARB, angiotensin II receptor blocker; IVC, inferior vena cava; LA, left atrial; 
LVEDD, left ventricular end-diastolic diameter. 
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Table 2. Outcome Measures 
 Control CHF - NYHA II CHF - NYHA III P ≤ 
n 8 5 5  
Tc-DTPA Clearance     
Half clearance time (min) 75.9 (70.3-84.8)a 71.2 (54.0-73.2)b 48.4 (40.2-58.1)c 0.001 
Plasma catecholamines     
Epinephrine (pg/ml) 75 (31-126) 152 (62-199) 126 (108-161) 0.136 
Nor-epinephrine (pg/ml) 1171 (781-1499) 1169 (936-1169) 1776 (1137-1986) 0.112 
Aldosterone (pg/ml) 417 (381-417) 741 (502-957) 747 (538-791) 0.145 
Data are presented as median (25th-75th percentiles) and analysed by Jonkheere-Terpstra test 
for ordered variables.  Superscripts represent differences by pairwise comparison at P ≤ 0.05. 
Tc-DTPA, technetium-99m-diethyltriaminepentaaceticacid. 
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Highlights: 
 
 Alveolar fluid clearance measured as half time DTPA clearance was significantly faster in 
CHF patients than controls 
 This was further defined by NYHA classification supporting an association between 
increasing alveolar fluid clearance and disease severity in CHF 
 This finding supports the concept of controlled bi-directional fluid flux in CHF associated 
with increasing Pmv, and represents another defence mechanism of the lung against 
pulmonary oedema. 
